Antituberculosis drug resistance and associated risk factors in the European section of Turkey.

Basit Öğe Kaydı
dc.authorscopusid23060531400
dc.authorscopusid6602943152
dc.authorscopusid6701537113
dc.authorscopusid6602215813
dc.authorscopusid7003843568
dc.authorscopusid6603657591
dc.contributor.authorKarabay O.
dc.contributor.authorOtkun M.
dc.contributor.authorAkata F.
dc.contributor.authorKarlikaya C.
dc.contributor.authorTugrul M.
dc.contributor.authorDündar V.
dc.date.accessioned2024-06-12T10:28:08Z
dc.date.available2024-06-12T10:28:08Z
dc.date.issued2004
dc.description.abstractBACKGROUND: We carried out this study in order to establish the prevalence of antituberculosis drug resistance in Mycobacterium tuberculosis strains and to determine risk factors for the development of resistance in Trakya region of Turkey. METHODS: Pattern of drug resistance in 214 M. tuberculosis isolates from patients with tuberculosis treated at the regional tuberculosis dispensaries were included in the study. RESULTS: Isolates of 105 (49.1%) were resistant to only one drug, and 62 (29.0%) were resistant to more than one drug. The total resistance rates to streptomycin, isoniazid, rifampicin, ethambutol and isoniazid + rifampicin were 29.0%, 27.1%, 21.5%, 10.3% and 11.6%, respectively. The secondary resistance rates in all drugs and combinations were higher than primary resistance rates (p<0.001). Step wise logistic regression revealed that (i) non-compliance with treatment increases the chances of development of resistance by 15 times [p<0.00001, 95% confidence intervals (95% CI) : 4.16 to 56.70], and (ii) a regimen of inadequate treatment increases the chance of development of drug resistance by 10.5 times (p<0.01, 95% CI=2.66 to 49.80). CONCLUSIONS: We propose that specially trained physicians should institute antituberculosis therapy and medication should be practiced under direct observation in this region.en_US
dc.identifier.endpage177en_US
dc.identifier.issn0377-9343
dc.identifier.issue3en_US
dc.identifier.pmid15553205en_US
dc.identifier.scopus2-s2.0-16644401816en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage171en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17086
dc.identifier.volume46en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofThe Indian journal of chest diseases & allied sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTuberculostatic Agent; Adolescent; Adult; Aged; Antibiotic Resistance; Article; Child; Drug Effect; Female; Human; Lung Tuberculosis; Male; Microbiological Examination; Microbiology; Middle Aged; Mycobacterium Tuberculosis; Preschool Child; Risk Factor; Tuberculosis; Turkey (Republic); Adolescent; Adult; Aged; Aged, 80 And Over; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium Tuberculosis; Risk Factors; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Turkeyen_US
dc.titleAntituberculosis drug resistance and associated risk factors in the European section of Turkey.en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu